(Q42226525)

19 October 2017

Disease progression, drug action and Parkinson's disease: why time cannot be ignored (English)

1 reference

19 October 2017

1 reference

2

John G Nutt

1 reference

19 October 2017

Nick Holford

1

1 reference

19 October 2017

19 December 2007

1 reference

European Journal of Clinical Pharmacology

19 October 2017

1 reference

19 October 2017

64

1 reference

19 October 2017

2

1 reference

19 October 2017

207-216

1 reference

https://scigraph.springernature.com/pub.10.1007/s00228-007-0427-9

19 October 2017

0 references

cites work

Modeling the short- and long-duration responses to exogenous levodopa and to endogenous levodopa production in Parkinson's disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

More efficient clinical trials through use of scientific model-based statistical tests

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs Later L-DOPA.

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Population pharmacokinetics and pharmacodynamics of oral levodopa in parkinsonian patients

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

The response to levodopa in Parkinson's disease: imposing pharmacological law and order

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Dopamine turnover and glutathione oxidation: implications for Parkinson disease

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

The oxidant stress hypothesis in Parkinson's disease: evidence supporting it

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Considerations in the management of parkinsonism

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations

26 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Modification of Parkinsonism--chronic treatment with L-dopa

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Pharmacokinetic and pharmacodynamic modeling of L-dopa plasma concentrations and clinical effects in Parkinson's disease after Sinemet.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Disease progression and pharmacodynamics in Parkinson disease - evidence for functional protection with levodopa and other treatments.

29 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Pharmacokinetic and pharmacodynamic changes during the first four years of levodopa treatment in Parkinson's disease

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Importance of within subject variation in levodopa pharmacokinetics: a 4 year cohort study in Parkinson's disease

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease

17 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3390311

Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation

17 August 2018

1 reference

12 December 2020

1 reference

12 December 2020

DATATOP: a multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group

1 reference

12 December 2020

Effect of deprenyl on the progression of disability in early Parkinson's disease

1 reference

12 December 2020

Kinetic-dynamic relationship of oral levodopa: Possible biphasic response after sequential doses in Parkinson's disease

1 reference

12 December 2020

Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon

1 reference

12 December 2020

The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomatic

1 reference

12 December 2020

Pharmacodynamic modeling of oral levodopa: clinical application in Parkinson's disease

1 reference

12 December 2020

10.1007/S00228-007-0427-9

Identifiers

DOI

1 reference

release_nuxud32khvdo7bqhgcrofxelsi

19 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/nuxud32khvdo7bqhgcrofxelsi

24 November 2022

mapped directly with Wikidata item

PMCID

3390311

1 reference

19 October 2017

1 reference

PMCID

3390311